Please use this identifier to cite or link to this item:
Title: Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria
Authors: C. Luxemburger
F. O. Ter Kuile
F. Nosten
G. Dolan
J. H. Bradol
L. Phaipun
T. Chong-Suphajaisiddhi
N. J. White
Shoklo Malaria Research Unit
Mahidol University
University of Amsterdam
Nuffield Department of Clinical Neurosciences
Keywords: Immunology and Microbiology;Medicine
Issue Date: 1-Jan-1994
Citation: Transactions of the Royal Society of Tropical Medicine and Hygiene. Vol.88, No.2 (1994), 213-217
Abstract: The therapeutic efficacy and toxicity of a combination of low dose mefloquine (15 mg/kg) plus artesunate 10 mg/kg in one day (MA) was compared with the currently used regimen of high dose mefloquine (25 mg/kg) (MQ) in 552 patients with uncomplicated falciparum malaria in an area of multi-drug resistance on the Thai-Burmese border. MA gave faster clinical and parasitological responses and prevented early treatment failure; 15 patients in the MQ group (6%)were early failures ( < 9 d) compared with none receiving MA (P = 0.0001). Overall failure rates by day 28 were 19% in the MA group and 24% in with MQ group (relative risk (RR) = 0.78, 95% confidence interval(CI) 0.54−1.12). In the subgroup of patients who required re-treatment, MA proved significantly more effectivethan MQ; failure rates were 25% and 52% respectively (RR = 0.49, 95% CI = 0.29−0.83). Treatment failures were associated with mefloquine treatment in the previous month (RR = 1.72, 95% CI = 1.09−2.70) and diarrhoea (RR = 1.55, 95% CI = 1.05−2.28). Gastrointestinal side-effects and dizziness were more likely in the MQ group. There was no evident adverse effect as sociated with artesunate. A single day's treatment with artesunate augments the antimalarial efficacy of mefloquine. © 1994 Oxford University Press.
ISSN: 18783503
Appears in Collections:Scopus 1991-2000

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.